This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.
Stocks · News reference
Kura Oncology Appoints Jennifer Fulk As CFO, Effective September 8
– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30
Caspian Therapeutics And Kura Oncology Released Comprehensive Preclinical Data Supporting KO-7246 For Diabetes
Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura"))) today announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for
Kura Oncology Q2 2026 Earnings Call Transcript
On Wednesday, Kura Oncology (NASDAQ:KURA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts